Plasma Protease C1 Inhibitor Market

Hereditary angioedema treatment is likely to lead application at 76.0% share in 2026. Plasma-derived C1 esterase inhibitors are set to follow with 69.0% share of product type in 2026. Treatment selection reflects diagnosis confirmation and attack profiles across acute or preventive care. Plasma availability and competition from non-plasma therapies represent principal commercial barriers.